A Sequential Multiple Assignment Randomised Trial (SMART) Of Nursing Interventions To Reduce Pain Associated With Chemotherapy Induced Peripheral Neuropathy
Funder
National Health and Medical Research Council
Funding Amount
$713,418.00
Summary
Modern chemotherapy treatments can result in damage to the peripheral nerves, resulting in a condition called peripheral neuropathy. This condition is characterised by a range of sensory and functional changes that can cause pain and reduced ability to perform daily activities. This project will test various non-pharmacological pain management measures to determine if they are effective in improving the quality of life of patients who experience this problem.
Prospective Longitudinal Study - Symptom Clusters & Their Effects - Physical & Psychogical Functioning Patients Metastat
Funder
National Health and Medical Research Council
Funding Amount
$149,599.00
Summary
People with advanced cancer often experience several concurrent debilitating symptoms, yet most symptom research focuses on the study of individual symptoms. This study aims to gain a better understanding of the patterns and effects of specific groups of symptoms across the trajectory of a patient's illness following diagnosis of advanced cancer. Such knowledge is critical to the development of more focused symptom assessment processes and more appropriately targeted interventions.
A Multi-site Randomised Controlled Trial Comparing The Severity Of Constipation Symptoms Experienced By Palliative Care Patients Receiving Usual Care Compared To Those Diagnosed And Managed According To The Underlying Pathophysiology.
Funder
National Health and Medical Research Council
Funding Amount
$498,795.00
Summary
This research aims to consider whether the problems of constipation in palliative care are less severe when the physical changes that underlie the problem are explored.
Development And Evaluation Of A Tailored Fatigue Self-management Behavioural Intervention For Patients With Advanced Cancer
Funder
National Health and Medical Research Council
Funding Amount
$157,836.00
Summary
Fatigue (tiredness and exhaustion) is one of the most distressing symptoms experienced by 74% of patients with advanced cancer. This research program aims to develop a sustainable intervention for enabling patients to use self-management strategies, thereby reducing the severity and impact of fatigue.
Systematic Expansion Of The Clinical Evidence Base In Opioid Prescribing For Refractory Dyspnoea At The End Of Life
Funder
National Health and Medical Research Council
Funding Amount
$414,535.00
Summary
Morphine can relieve breathlessness in the palliative setting. But many important questions remain. What is the best dose, should the dose change over time, do different medications provide the same relief, and how common is dyspnoea in the general population? This three part project will extend our knowledge to answer these questions. Population data will provide critical background to plan best care for future palliative patients distressed by breathlessness.
Cellular Modelling Of Attention Deficit Hyperactivity Disorder (ADHD) Risk Genes
Funder
National Health and Medical Research Council
Funding Amount
$753,746.00
Summary
Attention deficit hyperactivity disorder is a prevalent behavioural disorder affecting 7.4% of Australian children and adolescents. It has a strong genetic component with high heritability estimates (75–90%) comparable to other serious mental illness such as autism and schizophrenia. Identification and functional characterization of the genetic causes of this disorder will enhance our knowledge of its neurobiology and revolutionise the drug treatment of the disorder.
The Analgesic Evaluation Of Novel Natural Products From The Australian Plant Barringtonia Acutangula
Funder
National Health and Medical Research Council
Funding Amount
$174,500.00
Summary
This project aims to evaluate the analgesic activity of several novel natural products that have been isolated from the Australian plant Barringtonia acutangula. An Australian Aboriginal tribe have been known to use B. acutangula aqueous bark extracts for its analgesic properties. Griffith University researchers have confirmed this biological activity in the crude aqueous bark extract. A large scale extraction and isolation process will obtain the novel compounds in sufficient quantities that wi ....This project aims to evaluate the analgesic activity of several novel natural products that have been isolated from the Australian plant Barringtonia acutangula. An Australian Aboriginal tribe have been known to use B. acutangula aqueous bark extracts for its analgesic properties. Griffith University researchers have confirmed this biological activity in the crude aqueous bark extract. A large scale extraction and isolation process will obtain the novel compounds in sufficient quantities that will allow for their pharmacological evaluation as potential analgesic drugs.Read moreRead less
Refining And Testing A Promising New Treatment For Chronic Pain.
Funder
National Health and Medical Research Council
Funding Amount
$743,947.00
Summary
Chronic pain costs Australia about 35 billion dollars a year. Recent scientific discoveries show that treatment aimed at correcting problems in how the brain processes sensory input can reduce pain and disability. This project will clarify some key aspects of these problems and use that information to make final adjustments to an already very promising treatment. We will then test the treatment in a definitive and comprehensive clinical trial.
Randomised Double-blind Controlled Trial Of Oxygen Versus Air To Palliate Intractable End-of-life Dyspnoea When Pa02 >55
Funder
National Health and Medical Research Council
Funding Amount
$463,318.00
Summary
Shortness of breath at the end-of-life is one of the most feared symptoms. Unlike most other symptoms, it worsens as death approaches. Despite the fact that more than 50,000 Australian will die an expected death in the next year, of whom the majority will have breathlessness toward the end-of-life, we know little about how best to treat this symptom. Oxygen is frequently introduced but we have not identified whether it is more effective than medical air, and, if it is more effective, which patie ....Shortness of breath at the end-of-life is one of the most feared symptoms. Unlike most other symptoms, it worsens as death approaches. Despite the fact that more than 50,000 Australian will die an expected death in the next year, of whom the majority will have breathlessness toward the end-of-life, we know little about how best to treat this symptom. Oxygen is frequently introduced but we have not identified whether it is more effective than medical air, and, if it is more effective, which patients would most benefit from it. Because of this lack of evidence, oxygen is only funded in Australia in community settings for people who have severely low oxygen levels in their blood. Palliative oxygen is provided on a compassionate basis at times but this is on an ad hoc basis and does not ensure equitable access for people at the end of life who experience shortness of breath. This multi-centre study will compare oxygen and air, with neither the participant nor caring clinicians knowing which treatment they will receive. After careful explanation, volunteers who agree to participate will be asked to use the oxygen machine for at least 15 hours each day for 7 days and fill out a diary twice each day. Five centres across Australia are planning to enroll 240 participants in this study. Outcomes will include whether the sensation of breathlessness has improved, the overall quality of life while being treated, the ability to perform activities of daily living and any side effects experienced. This study is eagerly awaited by clinicians and health planners not only in Australia but in North America and Europe. This study will provide data in a long-standing international debate about the role of oxygen in people with relatively normal levels of oxygen in their blood who suffer from shortness of breath at the end-of-life.Read moreRead less
Reduction Of Chronic Post-surgical Pain With Ketamine - ROCKet Study
Funder
National Health and Medical Research Council
Funding Amount
$4,823,395.00
Summary
Chronic post-surgical pain (CPSP) is a common complication of major surgery, and a significant burden on quality of life and ongoing health costs. Ketamine is a drug used by anaesthetists to treat severe acute surgical pain. Various small studies suggest that it may be unique in its ability to reduce the risk of CPSP. We propose a large trial of ketamine during & after anaesthesia for major surgery to test this. Demonstration of effectiveness would promote widespread change in clinical practice.